Georgia is currently home to 1925 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Cooperative Assessment of Late Effects for SCD Curative Therapies
NCT05153967
Recruiting
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400 births. Approximately 100,000 individuals are diagnosed with SCD in the United States. Mortality for children with SCD has decreased substantially over the past 4 decades, with \>99% of those born in high resource settings, including the United States, France, and England, now surviving to 18 years of age. However, the life expectancy of adults with SCD is severely shortened.... Read More
Gender:
ALL
Ages:
Between 4 years and 65 years
Trial Updated:
09/16/2024
Locations: Emory University School of Medicine, Atlanta, Georgia
Conditions: Sickle Cell Disease, Pulmonary Disease, Renal Disease, Heart Disease
Register for Updates
ZIP Study-OL Study of Safety, PK, Efficacy, PD, Immunogenicity of ATB200/AT2221 in Pediatrics Aged 0 to < 18 y.o. w/LOPD
NCT03911505
Recruiting
This is a Phase 3, open-label, multicenter study to evaluate the safety, PK, efficacy, PD, and immunogenicity of Cipaglucosidase Alfa/Miglustat treatment in enzyme replacement therapy (ERT)-experienced and ERT-naïve pediatric subjects with Pompe disease, aged 0 to \< 18 years
Gender:
ALL
Ages:
Between 0 years and 17 years
Trial Updated:
09/16/2024
Locations: Woodruff Memorial Research Building, Atlanta, Georgia
Conditions: Pompe Disease (Late-onset)
Register for Updates
Study of Biomarker-Based Treatment of Acute Myeloid Leukemia
NCT03013998
Recruiting
This screening and multi-sub-study Phase 1b/2 trial will establish a method for genomic screening followed by assigning and accruing simultaneously to a multi-study "Master Protocol (BAML-16-001-M1)." The specific subtype of acute myeloid leukemia will determine which sub-study, within this protocol, a participant will be assigned to evaluate investigational therapies or combinations with the ultimate goal of advancing new targeted therapies for approval. The study also includes a marker negativ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/16/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Previously Untreated Relapsed Refractory Acute Myeloid Leukemia
Register for Updates
A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)
NCT05686239
Recruiting
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer are: 1. Does RL-007 improve subjects performance in a set of cognitive tasks? 2. Which dose of RL-007 (20 mg or 40 mg) has a larger effect on cognitive performance? 3. How well do subjects tolerate RL-007? In the study, subjects will perform the cognitive tasks at the beginning to get familiar with... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
09/13/2024
Locations: Recognify Research Site, Atlanta, Georgia
Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Register for Updates
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
NCT05674656
Recruiting
The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA \[Ribonucleic Acid\] \< 50 \[cells per milliliter\] c/mL) children 6 to less than 12 years of age, weighing at least 25 kilogram (kg).
Gender:
ALL
Ages:
Between 6 years and 12 years
Trial Updated:
09/13/2024
Locations: GSK Investigational Site, Atlanta, Georgia
Conditions: HIV Infections
Register for Updates
Sugammadex vs Neostigmine Reversal in Pediatric Appendectomy
NCT05256901
Recruiting
This study is designed as a randomized controlled trial with patients assigned to neuromuscular reversal with either sugammadex or neostigmine/glycopyrrolate reversal. The study will not be blinded to the anesthesiologist to allow for appropriate decision-making on timing and dosage of reversal. This is a single-center study.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
09/13/2024
Locations: Children's Healthcare of Altanta, Atlanta, Georgia
Conditions: Appendicitis, Surgery
Register for Updates
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
NCT04038502
Recruiting
This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant prostate cancer. This trial will use olaparib or carboplatin as initial therapy with crossover to the alternate or second-line drug after first progression for patients with tumors containing BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L inactivating mutations. P... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
09/13/2024
Locations: Atlanta VA Medical and Rehab Center, Decatur, GA, Decatur, Georgia
Conditions: Metastatic Castrate Resistant Prostate Cancer, BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D, or RAD54L Mutations
Register for Updates
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
NCT06328686
Recruiting
This early phase I trial evaluates different administration techniques (oral or intravenous) for arginine and tests the safety of giving arginine with whole brain radiation therapy in patients who have cancer that has spread from where it first started (primary site) to the brain (brain metastases). Arginine is an essential amino acid. Amino acids are the molecules that join together to form proteins in the body. Arginine supplementation has been shown to improve how brain metastases respond to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/12/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Register for Updates
Virtual Rehabilitation in HCT
NCT05943964
Recruiting
Chronic GVHD (cGVHD) is a major cause of illness in patients who undergo hematopoietic transplantation (HCT). GVHD can affect any organ in the body, can require several years of treatment, and can impact the quality of life (QoL). Physical activity and exercise have been shown to enhance fitness and improve QoL in chronic illnesses including GVHD, however, patients often have barriers to attending sessions including distance, risk of infection, and physical therapists' lack of experience with pe... Read More
Gender:
ALL
Ages:
Between 8 years and 23 years
Trial Updated:
09/12/2024
Locations: Children's Healthcare of Atlanta, Atlanta, Georgia
Conditions: Hematopoietic Cell Transplant
Register for Updates
Association of Plant-based Diet and Gut Microbiome Signature with Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
NCT06595160
Recruiting
This study explores the relationship between pre-treatment dietary patterns, fecal microbiome, and response to chemotherapy in patients with pancreatic ductal adenocarcinoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia
Conditions: Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer AJCC V8
Register for Updates
NEXUS Aortic Arch Clinical Study to Evaluate Safety and Effectiveness
NCT04471909
Recruiting
Prospective, non-randomized, multi-center clinical investigation of the NEXUS™ Aortic Arch Stent Graft System (NEXUSTM) for the treatment of thoracic aortic lesions involving the aortic arch with a proximal landing zone, native or previously implanted surgical graft, in the ascending aorta and with a brachiocephalic trunk native landing zone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/11/2024
Locations: Emory University, Atlanta, Georgia
Conditions: Aortic Dissection, Aortic Aneurysm, Intramural Hematoma, Penetrating Aortic Ulcer
Register for Updates
Pectoralis Minor Release Versus Non-release in RSA
NCT06292169
Recruiting
The goal of this clinical trial is to assess if concomitant open pectoralis minor release would improve pain and outcomes after Reverse Shoulder Arthroplasty (RSA). The main questions it aims to answer are: * whether releasing the pectoralis minor prophylactically could have better pain relief * whether releasing the pectoralis minor prophylactically could have increased Range of motion (ROM) outcomes * whether releasing the pectoralis minor prophylactically could have higher final Patient Repo... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: Emory Clinic, Atlanta, Georgia
Conditions: Reverse Total Shoulder Arthroplasty, Rotator Cuff Tear Arthropathy, Advanced Glenohumeral Osteoarthritis
Register for Updates